# 20/20 Biolabs, Inc.: overview AIDX · Nasdaq · CIK 1139685 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/aidx.md) · [Financials](/companies/aidx/financials.md) · [Filings](/companies/aidx/filings.md) · [Insiders](/companies/aidx/insiders.md) Latest reported revenue: [$730.6k](/filings/0001213900-26-090042.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:Revenues, accession 0001213900-26-090042). ## Last eight quarters | Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $k | [554](/filings/0001213900-26-059542.md) | [535](/filings/0001213900-26-090042.md) | [353](/filings/0001213900-26-059542.md) | [731](/filings/0001213900-26-090042.md) | | Gross margin | % | [29.9%](/filings/0001213900-26-059542.md) | [30.5%](/filings/0001213900-26-090042.md) | [17.8%](/filings/0001213900-26-059542.md) | [41.7%](/filings/0001213900-26-090042.md) | | Operating margin | % | [(139.4%)](/filings/0001213900-26-059542.md) | [(158.1%)](/filings/0001213900-26-090042.md) | [(408.4%)](/filings/0001213900-26-059542.md) | [(170.3%)](/filings/0001213900-26-090042.md) | | Net margin | % | [(138.1%)](/filings/0001213900-26-090042.md) | [(157.2%)](/filings/0001213900-26-090042.md) | [(615.4%)](/filings/0001213900-26-090042.md) | [(206.2%)](/filings/0001213900-26-090042.md) | | Diluted EPS | $ per share | [(0.16)](/filings/0001213900-26-059542.md) | [(0.17)](/filings/0001213900-26-090042.md) | [(0.28)](/filings/0001213900-26-059542.md) | [(0.26)](/filings/0001213900-26-090042.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | | Revenue | $k | [1,752](/filings/0001213900-26-037667.md) | [2,045](/filings/0001213900-26-037667.md) | | Gross margin | % | [20.6%](/filings/0001213900-26-037667.md) | [29.6%](/filings/0001213900-26-037667.md) | | Operating margin | % | [(324.0%)](/filings/0001213900-26-037667.md) | [(162.9%)](/filings/0001213900-26-037667.md) | | Net margin | % | [(316.8%)](/filings/0001213900-26-037667.md) | [(182.8%)](/filings/0001213900-26-037667.md) | | Diluted EPS | $ per share | [(1.16)](/filings/0001213900-26-037667.md) | [(0.76)](/filings/0001213900-26-037667.md) | | Free cash flow | $k | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/aidx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Cresset Asset Management, LLC](/funds/1761013.md) | 2026-06-30 | $132.0k | 240,122 | | Reduced −24,246 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $28.6k | 52,087 | | New +52,087 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $27.0k | 49,141 | | New +49,141 | | [Atlantic Union Bankshares Corp](/funds/883948.md) | 2026-06-30 | $19.3k | 35,099 | | New +35,099 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $13.5k | 24,530 | | New +24,530 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $12.8k | 23,205 | | Added +6,978 | | [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $7.2k | 13,024 | | New +13,024 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $5.5k | 10,014 | | New +10,014 | | [MCDONALD PARTNERS LLC](/funds/1331074.md) | 2026-06-30 | $1.5k | 2,800 | | New +2,800 | | [SIGNATUREFD, LLC](/funds/1456048.md) | 2026-06-30 | $422 | 767 | | New +767 | ## Recent filings [All 162 filings](/companies/aidx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-21 | 20:10 ET | [DEF 14A](/filings/0001213900-26-111346.md) | Proxy statement, period 2026-12-09 | 0001213900-26-111346 | | 2026-09-18 | 20:05 ET | [8-K](/filings/0001213900-26-101405.md) | 5.07 Shareholder vote results | 0001213900-26-101405 | | 2026-09-10 | 20:10 ET | [8-K](/filings/0001213900-26-098792.md) | 3.01 Delisting notice | 0001213900-26-098792 | | 2026-09-02 | 20:32 ET | [8-K](/filings/0001213900-26-096743.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-096743 | | 2026-08-19 | 13:19 ET | [8-K](/filings/0001213900-26-091438.md) | 5.07 Shareholder vote results | 0001213900-26-091438 | | 2026-08-17 | 20:05 ET | [8-K](/filings/0001213900-26-090746.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-090746 | | 2026-08-14 | 20:07 ET | [10-Q](/filings/0001213900-26-090042.md) | Quarterly report, period 2026-06-30 | 0001213900-26-090042 | | 2026-08-05 | 16:00 ET | [8-K](/filings/0001213900-26-085514.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-085514 | | 2026-07-22 | 20:45 ET | [8-K](/filings/0001213900-26-080432.md) | 1.01 Entry into a material agreement; 3.01 Delisting notice; 9.01 Financial statements and exhibits | 0001213900-26-080432 | | 2026-07-01 | 19:28 ET | [8-K](/filings/0001213900-26-074182.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-074182 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-037667.md), filed Mar 31, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/1898975b-eace-4570-b3e0-2d2ef2234ce8) ## About the filer - CIK: 1139685 - Tickers: AIDX - Exchange: Nasdaq - SIC code: 8734 Services-Testing Laboratories - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.